These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 23524017)

  • 1. Bronchodilation and safety of supratherapeutic doses of salbutamol or ipratropium bromide added to single dose GSK961081 in patients with moderate to severe COPD.
    Norris V; Ambery C
    Pulm Pharmacol Ther; 2013 Oct; 26(5):574-80. PubMed ID: 23524017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD.
    Bateman ED; Kornmann O; Ambery C; Norris V
    Pulm Pharmacol Ther; 2013 Oct; 26(5):581-7. PubMed ID: 23538170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-acting dual bronchodilator therapy (indacaterol/glycopyrronium) versus nebulized short-acting dual bronchodilator (salbutamol/ipratropium) in chronic obstructive pulmonary disease: A double-blind, randomized, placebo-controlled trial.
    van Geffen WH; Carpaij OA; Westbroek LF; Seigers D; Niemeijer A; Vonk JM; Kerstjens HAM
    Respir Med; 2020 Sep; 171():106064. PubMed ID: 32917359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.
    Quinn D; Barnes CN; Yates W; Bourdet DL; Moran EJ; Potgieter P; Nicholls A; Haumann B; Singh D
    Pulm Pharmacol Ther; 2018 Feb; 48():71-79. PubMed ID: 28987804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute effects of higher than standard doses of salbutamol and ipratropium on tiotropium-induced bronchodilation in patients with stable COPD.
    Cazzola M; Santus P; D'Adda A; Pizzolato S; Di Marco F; Centanni S
    Pulm Pharmacol Ther; 2009 Jun; 22(3):177-82. PubMed ID: 19038356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of ipratropium bromide/salbutamol sulphate administered in a hydrofluoroalkane metered-dose inhaler for the treatment of COPD.
    Bhattacharya A; Bhargava S; Singh V; Talwar D; Whig J; Rebello J; Purandare S; Gogtay J
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1469-76. PubMed ID: 27418820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
    Balkissoon R; Make B
    COPD; 2008 Aug; 5(4):221-7. PubMed ID: 18671147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nebulized formoterol effect on bronchodilation and satisfaction in COPD patients compared to QID ipratropium/albuterol MDI.
    Sutherland ER; Brazinsky S; Feldman G; McGinty J; Tomlinson L; Denis-Mize K
    Curr Med Res Opin; 2009 Mar; 25(3):653-61. PubMed ID: 19232039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bronchodilating effect of combined therapy with ipratropium bromide and ondansetron in patients with COPD.
    Pauwels R; Joos GF; Fogarty C; Faiferman I; Hirschberg S; Vessey R; Wouters EF
    Pulm Pharmacol Ther; 2008; 21(2):385-92. PubMed ID: 18023600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new class of bronchodilator improves lung function in COPD: a trial with GSK961081.
    Wielders PL; Ludwig-Sengpiel A; Locantore N; Baggen S; Chan R; Riley JH
    Eur Respir J; 2013 Oct; 42(4):972-81. PubMed ID: 23429913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daily variation in lung function in COPD patients with combined albuterol and ipratropium: results from a 4-week, randomized, crossover study.
    Singh D; Zhu CQ; Sharma S; Church A; Kalberg CJ
    Pulm Pharmacol Ther; 2015 Apr; 31():85-91. PubMed ID: 25197005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD.
    Singh D; Abbott-Banner K; Bengtsson T; Newman K
    Eur Respir J; 2018 Nov; 52(5):. PubMed ID: 30166326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting β2-adrenergic agonist, in asthma; a Phase II, randomized study.
    Singh D; Pujol H; Ribera A; Seoane B; Massana E; Astbury C; Ruiz S; de Miquel G
    BMC Pulm Med; 2014 Nov; 14():176. PubMed ID: 25398689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of nebulized levalbuterol in stable COPD.
    Datta D; Vitale A; Lahiri B; ZuWallack R
    Chest; 2003 Sep; 124(3):844-9. PubMed ID: 12970007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bronchodilator effects, pharmacokinetics and safety of PSX1002-GB, a novel glycopyrronium bromide formulation, in COPD patients; a randomised crossover study.
    Singh D; Ravi A; Reid F; Buck H; O'Connor G; Down G
    Pulm Pharmacol Ther; 2016 Apr; 37():9-14. PubMed ID: 26827913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma.
    Brookman LJ; Knowles LJ; Barbier M; Elharrar B; Fuhr R; Pascoe S
    Curr Med Res Opin; 2007 Dec; 23(12):3113-22. PubMed ID: 17999782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bronchodilator reversibility in patients with COPD revisited: short-term reproducibility.
    Pascoe S; Wu W; Zhu CQ; Singh D
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2035-40. PubMed ID: 27621609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 24-hour bronchodilation following a single dose of the novel β(2)-agonist olodaterol in COPD.
    van Noord JA; Smeets JJ; Drenth BM; Rascher J; Pivovarova A; Hamilton AL; Cornelissen PJ
    Pulm Pharmacol Ther; 2011 Dec; 24(6):666-72. PubMed ID: 21839850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast (15 mg), induce bronchodilation in patients with chronic obstructive pulmonary disease?
    Grootendorst DC; Gauw SA; Baan R; Kelly J; Murdoch RD; Sterk PJ; Rabe KF
    Pulm Pharmacol Ther; 2003; 16(2):115-20. PubMed ID: 12670781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.